Metallo-Therapy

Company Overview

Snapshot

Founded in January 2010 by Dr. Amal Ayoub, Metallo-Therapy operated with 1–10 employees and raised $4M across one funding round. In May 2011, the company secured funding from Arkin Tech.

Business overview

Metallo-Therapy develops contrast agents for precise tumor detection and monitoring using CT imaging. The company's proprietary gold nanoparticles (GNP) accumulate in malignant tumors, functioning as nano-markers to support and enhance applications in cancer patient management undergoing radiotherapy. Metallo-Therapy operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, serving the healthcare industry.

Strategic signal

In May 2011, Metallo-Therapy secured funding from Arkin Tech, signaling early investor confidence in its gold nanoparticle technology for cancer management. This investment highlighted the potential of its proprietary contrast agents for tumor detection and monitoring, positioning the company as an innovator in the diagnostics and medical technology space.

Company Intelligence Q&A

What is Metallo-Therapy's core technology?

Metallo-Therapy develops proprietary gold nanoparticles (GNP) that accumulate in malignant tumors, enabling precise tumor detection and monitoring using CT imaging. These GNPs also function as nano-markers to enhance radiotherapy applications.

When was Metallo-Therapy founded?

Metallo-Therapy was founded in January 2010.

Who is the founder of Metallo-Therapy?

Dr. Amal Ayoub is the founder of Metallo-Therapy.

What was a significant early investment in Metallo-Therapy?

In May 2011, Metallo-Therapy received funding from Arkin Tech, an investment fund focused on innovative healthcare technologies.

What is the primary sector Metallo-Therapy operates in?

Metallo-Therapy operates primarily in the Health Tech & Life Sciences sector, with a focus on Medical Devices and Diagnostics Devices.